Logo Pure Precision
U
Contact us
  • Precision Capturing®
    • Precision Capturing® Technology
    • Recombinant Protein Purification
    • Antibody Purification
    • Precision Capturing® Pipeline
    • Quality at Navigo Proteins
  • Precision Targeting
    • Precision Targeting Technology
    • Protein Drug Conjugates
    • Radio Conjugates
    • Cellular Therapy
    • Multispecific Ligands
    • Precision Targeting Pipeline
  • Company
    • Who we are
    • Team
  • Resources
    • Capturing – Blog
    • Capturing – Whitepapers
    • Capturing – Publications
    • Targeting – Publications
  • News
    • Press
    • Events
  • Career
    • Career
    • Open Positions
  • Contact
Navigo Proteins and Nostrum Biodiscovery announce a research collaboration to enhance Affilin® ligand discovery using cutting-edge AI and Molecular Modeling techniques

Navigo Proteins and Nostrum Biodiscovery announce a research collaboration to enhance Affilin® ligand discovery using cutting-edge AI and Molecular Modeling techniques

by NavigoProteins | Sep 6, 2023 | Press

Halle (Saale), Germany and Barcelona, Spain, September 06, 2023 – We are excited to announce a pioneering partnership between Nostrum Biodiscovery, a frontrunner in computational molecular engineering services, and Navigo Proteins, an innovator developing next...

Navigo and Mannin Sign Agreement to Develop Innovative Affinity Ligand Against a Novel Drug for the Treatment of COVID-19

by NavigoProteins | Sep 26, 2022 | Press

The Precision X affinity ligand will enable an innovative affinity chromatography step for the efficient purification of the non-Fc fusion protein allowing a mAb-like process architecture Halle/Saale, September 26, 2022 – Navigo Proteins GmbH (“Navigo”), a premier...

Navigo Proteins Successfully Develops Affinity Resin against Ferritin for blood fraction processing

by NavigoProteins | Jul 20, 2022 | Press

Affinity resin enables efficient capture of Ferritin from blood fractions despite low serum concentrations Halle/Saale, Germany, July 20th, 2022. Navigo Proteins GmbH (“Navigo”), a premier protein engineering company and developer of affinity ligands for custom...

Navigo Proteins GmbH Announces Extension of Partnership with ITM for Targeted Radio Conjugates

by NavigoProteins | Oct 7, 2021 | Press

Halle/Saale, Germany, October 7th, 2021. – Navigo Proteins, a premier protein engineering company developing optimized scaffold protein-based affinity ligands from its Precision Targeting toolbox today announces the extension of their ongoing partnership with ITM SE,...

Repligen and Navigo Proteins Announce the Launch of an Affinity Resin for the Purification of COVID-19 Vaccines

by NavigoProteins | Feb 8, 2021 | Press

 WALTHAM, Mass., and HALLE (Saale), Germany – February 8, 2021 – Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo Proteins GmbH (“Navigo”), a premier protein engineering company specializing in...
« Older Entries
Next Entries »

Recent Posts

  • Navigo Proteins Announces Strategic R&D Collaboration with SCK CEN to Develop Targeted Radiotheranostics
  • Navigo Proteins and VERAXA Biotech Initiate Research Collaboration to Establish Pre-Targeting Strategies for Novel Affilin® Radio Conjugates
  • Simplified downstream processing for protein therapeutics with rapid custom affinity ligand discovery and affinity resin development
  • Affinity Chromatography for Recombinant Protein Purification
  • Artificial Protein A for Antibody and Non-Antibody Purification

Recent Comments

    Navigo Proteins GmbH
    Heinrich-Damerow-Straße 1
    06120 Halle (Saale)
    Germany

    Phone: +49 345 27996-330
    Fax: +49 345 27996-332
    E-Mail: info@navigo-proteins.com

    Precision Capturing®
    Precision Targeting
    Company
    News
    Career
    Contact
    Imprint
    Disclaimer
    Data Protection

    Social Media

    • Follow

    © 2024 Navigo Proteins GmbH